Harrington Investments’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.47M | Buy |
30,629
+310
| +1% | +$13.3K | 0.71% | 44 |
|
|
2026
Q1 | $1.11M | Buy |
30,319
+3,400
| +13% | +$161K | 0.59% | 49 |
|
|
2025
Q4 | $1.37M | Buy |
26,919
+1,165
| +5% | +$59.6K | 0.69% | 50 |
|
|
2025
Q3 | $1.43M | Sell |
25,754
-65
| -0.3% | -$3.81K | 0.71% | 47 |
|
|
2025
Q2 | $1.78M | Sell |
25,819
-135
| -0.5% | -$9.18K | 0.94% | 38 |
|
|
2025
Q1 | $1.8M | Sell |
25,954
-221
| -0.8% | -$18.3K | 1.02% | 36 |
|
|
2024
Q4 | $2.25M | Buy |
26,175
+80
| +0.3% | +$8.65K | 1.24% | 29 |
|
|
2024
Q3 | $3.11M | Sell |
26,095
-1,095
| -4% | -$146K | 1.7% | 20 |
|
|
2024
Q2 | $3.88M | Sell |
27,190
-3,428
| -11% | -$454K | 2.2% | 14 |
|
|
2024
Q1 | $3.93M | Sell |
30,618
-1,296
| -4% | -$154K | 2.25% | 13 |
|
|
2023
Q4 | $3.3M | Sell |
31,914
-2,660
| -8% | -$263K | 2.05% | 15 |
|
|
2023
Q3 | $3.14M | Sell |
34,574
-572
| -2% | -$50.4K | 2.16% | 13 |
|
|
2023
Q2 | $2.84M | Sell |
35,146
-110
| -0.3% | -$8.99K | 1.87% | 20 |
|
|
2023
Q1 | $2.81M | Sell |
35,256
-220
| -0.6% | -$15.6K | 1.94% | 18 |
|
|
2022
Q4 | $2.4M | Sell |
35,476
-254
| -0.7% | -$14.9K | 1.74% | 24 |
|
|
2022
Q3 | $1.78M | Hold |
35,730
| – | – | 1.38% | 28 |
|
|
2022
Q2 | $1.99M | Buy |
35,730
+40
| +0.1% | +$2.22K | 1.48% | 22 |
|
|
2022
Q1 | $1.98M | Sell |
35,690
-76
| -0.2% | -$3.9K | 1.19% | 29 |
|
|
2021
Q4 | $2M | Sell |
35,766
-570
| -2% | -$30.9K | 1.08% | 31 |
|
|
2021
Q3 | $1.74M | Sell |
36,336
-200
| -0.5% | -$9.67K | 1.01% | 33 |
|
|
2021
Q2 | $1.53M | Sell |
36,536
-300
| -0.8% | -$11.6K | 0.91% | 35 |
|
|
2021
Q1 | $1.24M | Sell |
36,836
-74
| -0.2% | -$2.64K | 0.78% | 42 |
|
|
2020
Q4 | $1.29M | Sell |
36,910
-2,174
| -6% | -$75.1K | 0.86% | 39 |
|
|
2020
Q3 | $1.36M | Sell |
39,084
-2,800
| -7% | -$93.3K | 0.96% | 37 |
|
|
2020
Q2 | $1.37M | Buy |
41,884
+50
| +0.1% | +$1.6K | 1.07% | 36 |
|
|
2020
Q1 | $1.26M | Sell |
41,834
-350
| -0.8% | -$10.4K | 1.18% | 34 |
|
|
2019
Q4 | $1.22M | Sell |
42,184
-1,996
| -5% | -$55.3K | 0.95% | 40 |
|
|
2019
Q3 | $1.14M | Sell |
44,180
-250
| -0.6% | -$6.32K | 0.94% | 39 |
|
|
2019
Q2 | $1.13M | Sell |
44,430
-40
| -0.1% | -$989 | 0.93% | 39 |
|
|
2019
Q1 | $1.16M | Sell |
44,470
-3,130
| -7% | -$76.9K | 1% | 40 |
|
|
2018
Q4 | $1.1M | Sell |
47,600
-700
| -1% | -$15.6K | 1.05% | 41 |
|
|
2018
Q3 | $1.14M | Sell |
48,300
-1,300
| -3% | -$31.7K | 0.9% | 41 |
|
|
2018
Q2 | $1.14M | Sell |
49,600
-4,700
| -9% | -$112K | 0.97% | 40 |
|
|
2018
Q1 | $1.34M | Buy |
54,300
+580
| +1% | +$15.2K | 1.1% | 40 |
|
|
2017
Q4 | $1.44M | Sell |
53,720
-470
| -0.9% | -$12K | 1.2% | 35 |
|
|
2017
Q3 | $1.3M | Buy |
+54,190
| New | +$1.22M | 1.25% | 34 |
|
Other funds holding NVO
SRIM
MG
SAM
GA
AIIMS
QI
AA
Harrington Investments's NVO Position: Q2 2026 in Review
Harrington Investments increased its Novo Nordisk (NVO) stake by 1% in Q2 2026, buying an estimated $13.3K and bringing the position to 30,629 shares worth $1.47M. The position accounts for 0.71% of the portfolio, ranked #44.
Harrington Investments first reported a position in NVO in Q3 2017 and has held it in 36 quarters since. The position peaked at $3.93M in Q1 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Harrington Investments held 30,629 shares of Novo Nordisk worth $1.47M as of Q2 2026.
- Harrington Investments bought 310 Novo Nordisk shares in Q2 2026, an estimated $13.3K.
- Novo Nordisk made up 0.71% of Harrington Investments's portfolio in Q2 2026, its #44 holding.
- Harrington Investments first reported a position in Novo Nordisk in Q3 2017 and has held it in 36 quarters since.
- Harrington Investments's Novo Nordisk position peaked at $3.93M in Q1 2024.
- 580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Harrington Investments's 13F filing for Q2 2026, filed 23 Jul 2026.